Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

Kirschbaum M; Frankel P; Popplewell L; Zain J; Delioukina M; Pullarkat V; Matsuoka D; Pulone B; Rotter AJ; Espinoza Delgado I; Nademanee A; Forman SJ; Gandara D; Newman E

首页> 外文期刊>Journal of Clinical Oncology >Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

【24h】

Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

机译：伏立诺他II期研究用于治疗复发性或难治性惰性非霍奇金淋巴瘤和套细胞淋巴瘤。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

PURPOSE: We performed a phase II study of oral vorinostat, a histone and protein deacetylase inhibitor, to examine its efficacy and tolerability in patients with relapsed/refractory indolent lymphoma. PATIENTS AND METHODS: In this open label phase II study (NCT00253630), patients with relapsed/refractory follicular lymphoma (FL), marginal zone lymphoma (MZL), or mantle cell lymphoma (MCL), with

机译：目的：我们进行了口服伏立诺他（组蛋白和蛋白质脱乙酰基酶抑制剂）的II期研究，以检查其对复发/难治性惰性淋巴瘤患者的疗效和耐受性。病人和方法：在这项开放标签的II期研究（NCT00253630）中，复发性/难治性滤泡性淋巴瘤（FL），边缘区淋巴瘤（MZL）或套细胞淋巴瘤（MCL）的患者，先有

著录项

来源
《Journal of Clinical Oncology》 |2011年第9期|共6页
作者
Kirschbaum M; Frankel P; Popplewell L; Zain J; Delioukina M; Pullarkat V; Matsuoka D; Pulone B; Rotter AJ; Espinoza Delgado I; Nademanee A; Forman SJ; Gandara D; Newman E;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. [J] . Kirschbaum M, Frankel P, Popplewell L, Journal of Clinical Oncology . 2011,第9期

机译：伏立诺他II期研究用于治疗复发性或难治性惰性非霍奇金淋巴瘤和套细胞淋巴瘤。
2. A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma [J] . OguraM., AndoK., SuzukiT., British Journal of Haematology . 2014,第6期

机译：伏立诺他用于多发性或难治性惰性B细胞非霍奇金淋巴瘤和套细胞淋巴瘤患者的多中心II期研究
3. A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma [J] . OguraM., AndoK., SuzukiT., British Journal of Haematology . 2014,第6期

机译：伏立诺他用于多发性或难治性惰性B细胞非霍奇金淋巴瘤和套细胞淋巴瘤患者的多中心II期研究
4. New biologic agents for the treatment of cutaneous T-cell lymphoma. [C] . Vittorio CC, Junkins Hopkins JM, McGinnis KS, World Congress on Cancers of the Skin . 2002

机译：用于治疗皮肤T细胞淋巴瘤的新生物剂。
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkins Lymphoma and Mantle Cell Lymphoma [O] . Mark Kirschbaum, Paul Frankel, Leslie Popplewell, -1

机译：伏立诺他治疗复发或难治性惰性非霍奇金淋巴瘤和套细胞淋巴瘤的II期研究
7. Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma [O] . Kirschbaum, Mark, Frankel, Paul, Popplewell, Leslie, 2011

机译：伏立诺他治疗复发或难治性惰性非霍奇金淋巴瘤和套细胞淋巴瘤的II期研究

Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

摘要

著录项

相似文献

相关主题

期刊订阅